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Summary
A bacterial pathogen that is important in both urinary tract and intestinal infections is Escherichia
coli which expresses Dr or related adhesins. In this report, we present a model for testing cell-cell
interaction, usingboth molecularly characterized laboratory cells that express recombinant molecules
of human decay-accelerating factor (DAF), and recombinant bacterial Dr colonization factors.
Dr adhesin ligand was identified as DAF (CD55), a membrane protein that protects autologous
tissues from damage due to the complement system. Structure-function studies mapped the adhesin-
binding site on the DAF molecule. A single-point substitution in the third short consensus repeat
domain, Sertbs to Leu, corresponding to the Dr' to Drb allelic polymorphism, caused complete
abolition of adhesin binding to DAR
T
he host-parasite interaction may occur via specific bac-
terial lectin-like molecules, called adhesins, fimbriae, or
pili (1) . Bacterial adhesin-mediated attachment may result in
the colonization ofhost tissues and may lead to an infectious
process (2) . A bacterial pathogen that is important in both
urinary tract (UT)' and intestinal infections is Escherichia
coli, which expresses Dr or related adhesins, afimbrial adhesin
I (AFA-I), afimbrial adhesin III (AFA-III), and diarrhea-
associated F1845 (3-5). These adhesins have similar gene or-
ganizations, and their close relationship is confirmed by
the nucleotide sequence of Dr adhesin with other Dr-like
adhesins (b).
E. coli-bearing adhesins of the Dr family are found most
frequently in the UT, and account for 27% of clinical E. coli
isolates that cause symptomatic UT infection (7). Others fre-
quently seen are P and type 1 fimbriae-positive E. coli (8, 9).
Moreover, Dr adhesin is a possible virulence factor of symp-
tomatic UT infection, including cystitis and protracted
diarrhea-associated strains (3, 7, 10).
The Dr ligand for E. coli, Dr adhesins, has been found
on erythrocytes and in several other tissues, including the
1 Abbreviations used in this paper. AFA, afimbrial adhesin; CHO, Chinese
hamster ovary; DAF, decay-accelerating factor; GPI, glycosyl
phosphatidylinositol; MHT, minimal hemagglutination titer; SCR, short
consensus repeat (domain); S/T, serine/threonine-rich; UT, urinary tract.
uroepithelium ofthe lower and upper UT, renal tissue (base-
ment membranes and Bowman's capsule), and colonic glands.
Therefore, we propose that the Dr ligands in the aforemen-
tioned organs may support ascending colonization/infection
of UT by endogenous flora (11).
We havepreviously identified a Dr adhesin ligand in human
tissues based on the observation that the Dr adhesin does
not bind to erythrocytes of the rare Inab phenotype (12), a
null phenotype of the Cromer blood group (13) . The latter
was localized on a 70-kD glycoprotein (14) that subsequently
was identified by three groups of investigators (15-17) as decay-
accelerating factor (DAF, CD55), a membrane protein that
protects autologous tissues from damage due to the comple-
ment system (18, 19). The identity of the Dr adhesin ligand
as DAF-Cromer antigen was supported by the observation
(17) that the Dr adhesin did not bind to normal human
erythrocytes in the presence of purified DAF nor to affected
erythrocytes in the disease paroxysmal nocturnal hemoglo-
binuría, a condition whereby the cells lack all glycosyl phos-
phatidylinositol (GPI)-anchored membrane proteins, including
DAF (20-22). Thus, our hypothesis is that the Dr adhesin
might recognize DAF (Cromer antigen).
Direct evidence for DAF-Dr adhesin recognition may be
foundvia molecular characterization ofthe interaction ofDAF
and Dr adhesin. In this report, we present a model for testing
cell-cell interaction, using both molecularly characterized lab-
oratory cells that express recombinant molecules of human
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results with the model have led to the identification of DAF
as the ligand of the family of recombinant Dr and related
E. coli adhesins. Further, we have developed structure-func-
tion studies that have mapped the adhesin binding site on
the DAF molecule.
Materials and Methods
Bacterial Strains. E. coli HB101 strains containing plasmids
pBJN406, pILL22, pILL115, and pSSS1 that expressed Dr, AFA-I,
AFA-III, and F1845 adhesins, respectively, were grown on L-agar
plates supplied with appropriate antibiotics. Bacterial cells were col-
lected from the plates and a washed suspension of each strain was
made, with an OD of 0.6 at 600 rim. Twofold serial dilutions of
suspension were prepared to measure the minimal hemagglutina-
tion titer (MHT)for each E. coli strain, using 3% (vol/vol) human
groupO erythrocytes in 2% (x-methylmannose. Experiments were
performed with suspensions ofidentical MHT (1/64) and/or having
an identical OD of 0.6 at 600 nm.
Chinese HamsterOvary(CHO) Cell Transfectants Expressing DAF
andDAEDeletion Mutants. CHO cell transfectant clones that stably
express DAF cDNA or various DAF constructs have been previ-
ously reported (23). Briefly, the CHO cells were transfected with
10 ug of DNA in the expression vector SFFVneo (24) and 100
leg of lipofectin (25), and selectedin 0.25 mg/ml G418 (active drug).
Clones were produced by a number of rounds of sterile sorting
with flow cytometry, followed by cloning via limiting dilution (23).
Surface expression of DAF in the clones was measured by flow
cytometry of CHO cells treated with rabbit polyclonal or murine
monoclonal anti-human DAF (23), followed by appropriate FITC-
labeled second antibody.
Purification ofFimbriae
￿
Dr fimbrial protein was isolated by heat-
shock treatment, deoxycholate, urea, and sucrose purification steps,
as described previously (26).
CHOBinding Assay.
￿
CHO cells stably transfected with cDNA
for human DAF or DAF deletion mutants were cultured in Ham's
F12 medium supplemented with 10% FCS and grown to -70%
confluence in eight chamber slides (23). Suspensions of live E. coli
cells (300 A1 in PBS and 2% ot-methylmannose) were added to the
chambers containing CHO cells in quadruplicate, and incubated
for 30 min at room temperature; experiments were performed on
fixed and/or live CHO cells. Both methods gave similar results,
and therefore, fixed cells were used preferably. Chambers were
washed five times with PBS. One set of chambers was fixed for
10 minutes with cold acetone and stained for 45 s with safranin.
The stained chambers were examined under a phase-contrast mi-
croscope (Leica Inc., Deerfield, IL), and 100 CHO cells per well
were counted. The results were expressed as the mean number of
bacterial cells per CHO cell.
To count live bacterial cells, the other set of unfixed chambers
was swabbed, placed in 1 ml of sterile, cold distilled H20, and vor-
texed for 20 s. Then 10-fold dilutions were made and 50 p,l of each
dilution was spread onto Iragar plates and incubated at 37°C over-
night. CFU were determined and the mean number of bacterial
cells binding a single CHO cell was calculated. Experiments were
multiply performed, and although results with the two methods
were similar, the microscopic method showed less variability than
the CFU test, was highlyreproducible, and therefore used preferably.
Binding of Purified Dr Fimbriae to the CHO Cells.
￿
Briefly, 300
wl of purified fimbriae (20 Wg of protein per chamber) was added
to the slide containing various CHO transfectants, incubated for
30 min at +4°C, washed five times with PBS, and evaluated by
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indirect fluorescence with rabbit IgG, anti-Dr adhesin, and
fluorochrome-conjugated anti-rabbit IgG (27).
Results
Our previous data suggested that the E. coli Dr adhesin
bound to human DAF (12, 17). To confirm this finding and
to permit mapping of structure-function relationships in the
adhesin-ligand interaction, we established a system using
recombinant proteins for studying this interaction. E. coli
HB101 was transformed with a plasmid encoding the Dr
adhesin, and CHO cells were transfected with an expression
plasmid encoding DAF. A photomicrograph of the results
of a binding study showed that the Dr adhesin specifically
bound to human DAF (Fig. 1, upper panels). Further nega-
tive controls, using E. coli transformed with the vector without
the adhesin insert, demonstrated that binding was specific
for the adhesin (data not shown). Several experiments of this
type clearly confirmed that DAF was a ligand for the Dr
adhesin (Fig. 1, lower panel). In addition, binding could also
be seen using purified fimbriae and CHO transfectants ex-
pressing DAF (data not shown). Experiments were performed
also with live and fixed CHO cells and/or bacterial cells at
4°C, 25°C and 37°C. Changes in the conditions of the ex-
periment did not affect the binding results.
A series of CHO cell transfectant clones expressing in-
creasing amounts of DAF were used in binding assays with
E. coli recombinant strains expressing the Dr adhesin or one
of three other related adhesins, AFA-I, AFA-III, and F1845.
All four strains bound in a dose-dependent fashion (Fig. 2);
accordingly, DAF is a ligand for this entire family of adhesins.
The AFA-I adhesin showed the strongest attachmentcapacity
of these four recombinant strains, in that it was the only
adhesin to bind to the CHO cell clone expressing the lowest
amount of DAF.
Conversely, we also attempted to quantitate adhesins
through the use of serial dilutions of recombinant strains
(MHT 1/2 through 1/64). All four strains bound in a dose-
dependent fashion to DAF-positive cells (data not shown).
To eliminate potential differences in attachment to CHO cells
due to the variation in expression of adhesins, suspensions
ofrecombinant strains were used at the same MHT (as mea-
sured by the agglutination titer) . When necessary, before the
experiment, the MHT level of each strain was adjusted to
the same hemagglutinating activity (1/64), by diluting or
concentrating the suspension. For example, on the average,
a suspension with an OD of 0.6 at 600 nm had an MHT
titer of 1/64, and occasionally of 1/32. Therefore, clones were
approximately equal and only occasionally was a minor ad-
justment in OD necessary.
We next attempted to localize the binding sites of the
adhesins on the DAF molecule by using a series of DAF dele-
tion mutants. Most of the extracellular domains of DAF are
composed offour short consensus repeat (SCR) domains, each
of -60 amino acids and containing four conserved cysteines,
as well as other residues (28). A set of deletion mutants that
individually lack one of the four SCR units was expressedU
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U
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C
c z
30 -
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Vector DAF+
in CHO cells (29) . The surface expression of DAF by the
individual clones was approximately equal ; each deletion clone
expressed an amount ofDAF at least equal to the clone ex-
pressing wild-type DAF (varying less than twofold), as as-
sessed by flow cytometry (29) . The attachment of four recom-
binant E. coli strains that express Dr and related adhesins to
theseCHO transfectants expressing DAF and theDAF dele-
tion mutants were investigated (Fig . 3) . The binding pat-
terns for all four recombinantE. coli strains were similar, with
the exception of the binding toDAFASCR2 . SCR1 andSCR4
were not required for binding ofany ofthe adhesins, although
AFA-I and AFA-III did show a 50% reduction in binding,
with the removal ofSCR4 (Fig . 3) . Removal ofSCR3 abol-
ished binding of any ofthe adhesins, whereas removal ofSCR2
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Figure 1 .
￿
Upperpanels: Attachment ofE. coli BN406 bearing Dr hemag-
glutinin toCHO transfectants that expressDAF or vector incontrol. Left:
DAF-negative . Right. DAF-positive. Lowerpanel: Quantitation of attach-
ment of Dr-positive E. coli BN406 to DAF-positive and control DAF-
negative CHO cells.
abolished binding of all the adhesins, except for AFA-1, which
retained full binding to the DAFASCR2 mutant (Fig. 3) .
Thus, the adhesin binding site on DAF is similar, but dis-
tinct, for the four adhesins of the Dr adhesin family, and in-
volves SCR3 as well as SCR2 in some cases .
We had investigated previously a rare polymorphism of
human DAF, designated Dr(a-), and we found that it arose
from a point mutation that changed a single amino acid in
SCR3 : Sertbs in the high-frequency Dr- allele to Leu in the
rare Drb [Dr(a-)] allele (30) . We also found that erythrocytes
of the Drb phenotype did not bind Dr adhesin (12) . How-
ever, because Drb erythrocytes expressed only one-third the
levels of surface DAF found in Dr, erythrocytes, it could not
be ascertained if this lack of adhesin binding was a quantita-v
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Figure 2.
￿
Dose-dependent binding of E. coli strains that express recom-
binant adhesins to CHO transfectants that express increasing amounts of
surface DAR /, AFA-I; p, Dr; " , F1845; O, AFA-III.
tive or a qualitative effect. This becomes particularly relevant
because of the present results implicating SCR3 of DAF in
the adhesin-binding site. Thus, we studiedbinding of all four
of the Dr adhesin family members to CHO transfectants ex-
Figure 3.
￿
Attachment ofE. coli strains that express recombinant Dr and related adhesins AFAI, AFAIII, F1845 to CHO transfectants DAFO SCR1,
pressing equal amounts of the Dr' or Drb allele of DAF. The
results clearly showed that the single amino acid change be-
tween Dr- and Drb completely abolished binding of all four
of the adhesins (Fig. 4), suggesting that this amino acid po-
sition is part of the binding site.
The SCR domains that have been analyzed are the NH2-
terminal part of the DAF molecule, the remainder of which
consist of a 70-amino acid serine/threonine-rich (S/T) do-
main that is the site of extensive O-linked glycosylation (31)
and a GPI anchor (28). Binding studies showed no attach-
ment of any of the adhesins to a CHO cell transfectant ex-
pressing a DAFAS/T deletion mutant (Fig. 5). This was some-
what surprising as this domain is distant from the implicated
SCR3 domain. However, previous results had suggested that
this heavily O-glycosylated S/T domain serves as a spacer
projecting the complement regulatory SCR domains away
from the cell membrane (29). Reasoning that the same effect
might be operating with the E. coli attachment, adhesin
binding was also measured for a CHO transfectant expressing
a construct designated DAFAS/T + HLA, a chimeric mol-
ecule that consisted of the four SCR domains of DAF (but
lacking the S/T domain) and most (COOH terminus) of
the HLA-B44 molecule including the transmembrane and
cytoplasmic domains (29). This chimeric molecule that repo-
sitions the four SCR domains of DAF on HLA-B44 com-
pletely restored and even improved adhesin binding (Fig. 5).
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￿
Attachment ofE. coli that express recombinant Dr and related
adhesins to CHO transfectants expressing equal amounts of (") Dr- and
((]) Drb allele of DAR
Discussion
The present report describes a molecular model to study
host-pathogen interactions. Our approach permits an anal-
ysis of the cell-cell, adhesin-ligand, interaction in a molecu-
larlycharacterized system, in which both E. coli adhesin and
human tissue ligand have been isolated by molecular cloning
and expressed in well-characterized cell types. Studies on the
interaction between E. calf fimbriae and tissue ligands have
been performed predominantly on human erythrocytes,
purified glycoconjugates, or synthetic carbohydrates (1, 2, 32,
33). In such approaches, however, the antigenic complexity
of human red blood cells or the use of selected glycocon-
Dr F1845 AFA-I AFA-111
Dr AFA-1 AFA-III F1845
Figure 5.
￿
Attachment of E. coli strains that express recombinant Dr
and otherrelated adhesins to CHO transfectants expressing (open bar) DAFA
S/T deletion mutant and (hatched bar) DAFA S/T +HLA chimeric mole-
cules. (Solid bars) DAR
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jugates that are not necessarily a natural receptor present in
human tissue, may affect the identification ofnatural receptor
molecules. The present experiments indicated that DAF served
as a ligand for the family of E. coli Dr adhesins.
DAF is a GPI-anchored membrane protein that protects
host tissues from complement-mediated damage (28). DAF
regulates complement activation at the critical C3 conver-
tase step by preventing the association or by disassociating
the two components on the enzyme (34). The DAF mole-
cule contains four SCR domains, a S/T region, as well as
a GPI anchor. We have demonstrated previously that SCR2,
SCR3, and SCR4, but not SCR1 and Ser/Thr domains are
each necessary to protect transfected CHO cells from human
complement-mediated cytotoxicity, and that the level of pro-
tection increases with the expression of surface DAF (29).
The present study of DAF mutants has allowed us to define
the adhesin binding site on DAR First of all, this site is com-
posedexclusively ofa peptide sequence. DAF has three classes
on nonpeptide modification: a single N-linked oligosaccha-
ride (31) at the border of SCR1 and SCR2, multiple 0-linked
oligosaccharides attached to the S/T domain, and a GPI an-
chor at the carboxy terminus (29). The DAFASCR1 mutant
lacks the Winked oligosaccharide, and thus adhesin binding
to this molecule (Fig. 3) demonstrates that Winked oligosac-
charides are not required. The DAFOS/T + HLA construct
lacks the O-linked oligosaccharides; therefore, adhesinbinding
to this molecule (Fig. 5) demonstrates that O-linked oligosac-
charides are not required. Finally, this latter construct has
a transmembrane domain instead of a GPI anchor, and thus
the GPI anchor is not required for adhesin binding.
The peptide sequences in DAF that comprise the adhesin
binding site were localized by study of the DAFOSCR mu-
tants. SCR3 is critical for the binding of all four adhesins
(Fig. 3). Furthermore, a single-point substitution in SCR3,
Sertbs to Leu, corresponding to the Dr' to Drb allelic poly-
morphism (30), caused complete abolition of adhesin binding
to DAF (Fig. 4). This shows that our previous finding (12)
of a lack of reactivity of the Dr adhesin with Drb erythro-
cytes (that express only one-third the normal levels of DAF)
was due to the absence of an adhesin binding site rather than
to the lower expression of DAR The Dr' and Drb change
does not appear to affect the complement regulatory func-
tion of DAF (30), so the adhesin and complement binding
sites may not be the same.
The four adhesins exhibited some differences in theirbinding
sites on DAF, as the DAFOSCR4 mutant showed a moder-
atelyreduced binding ofthe AFA-I and AFA-III adhesins but
normal binding of the Dr and F1845 adhesins (Fig. 3). Thus,
this study supports our former proposal (5) that the binding
sites on DAF are similar but distinct for some of the adhesins.
This finding suggests that either the SCR2 or SCR4 peptide
sequence is directly necessary for binding of certain of the
adhesins or that the presence of these SCR domains affects
the conformation or accessibility ofthebinding site in SCR3.
Accessibility is also a factor for the S/T domain. The data
(Fig. 5) demonstrate that this region is acting as a nonspecific
spacer (in that it can be replaced by an unrelated sequence
from HLA-B44), presumably projecting the DAF bindingsite above the membrane for interaction with the adhesin.
A similar effect was seen for DAF interaction with its nat-
ural ligands Cab and C4b (29).
Amongtheimportant features ofourmodelis the expres-
sion of adhesins and ligands by the cells. This creates an op-
portunity to study cell-cell interaction, not only with re-
spect to receptor-ligand recognition, but it may also allow
us to design experiments on cell-to-cell interaction. Thesystem
has the advantage of assigning occurring phenomena to the
particular gene and the gene product; e.g., responses of live
DAF-bearing cells to colonization by live E. coli expressing
Dr adhesins, toxins, or their mutants.
The finding that Dr fimbriae recognize a specific SCR-3
epitope(s) of DAF is very intriguing and may represent an
example of bacterial colonization mechanisms that utilize
human immune system molecules. A well-known example
of this process wherebya humanpathogen invades andalters
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